Epredia and NovaScan Announce Intent to Enter U.S. Distribution Agreement for MarginScan™ Device for Non-Melanoma Skin Cancer Detection

PORTSMOUTH, N.H.--(BUSINESS WIRE)-- #CancerDiagnostics--Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that will support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Av